Q3 Earnings Forecast for Ardelyx Issued By Leerink Partnrs

Ardelyx, Inc. (NASDAQ:ARDX) – Equities research analysts at Leerink Partnrs issued their Q3 2025 earnings estimates for Ardelyx in a report released on Thursday, February 20th. Leerink Partnrs analyst R. Ruiz expects that the biopharmaceutical company will post earnings per share of ($0.03) for the quarter. The consensus estimate for Ardelyx’s current full-year earnings is ($0.18) per share. Leerink Partnrs also issued estimates for Ardelyx’s Q4 2025 earnings at ($0.01) EPS, FY2026 earnings at $0.40 EPS and FY2027 earnings at $1.00 EPS.

Ardelyx (NASDAQ:ARDX) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.02. Ardelyx had a negative net margin of 11.73% and a negative return on equity of 25.74%. The company had revenue of $116.13 million for the quarter, compared to analyst estimates of $111.16 million.

A number of other equities research analysts have also recently issued reports on the company. Citigroup cut their target price on Ardelyx from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Monday, November 4th. Piper Sandler lifted their price objective on shares of Ardelyx from $7.00 to $8.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Cantor Fitzgerald upgraded shares of Ardelyx to a “strong-buy” rating in a research report on Thursday, January 30th. Raymond James reissued a “strong-buy” rating and issued a $13.00 price target (down previously from $15.00) on shares of Ardelyx in a research note on Friday. Finally, Jefferies Financial Group dropped their price target on Ardelyx from $11.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, January 2nd. Three investment analysts have rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.93.

Ardelyx Stock Performance

Ardelyx stock opened at $5.06 on Monday. The company has a market cap of $1.20 billion, a PE ratio of -31.59 and a beta of 0.85. The company has a fifty day moving average price of $5.30 and a two-hundred day moving average price of $5.63. The company has a debt-to-equity ratio of 0.64, a current ratio of 4.03 and a quick ratio of 3.87. Ardelyx has a 12 month low of $4.32 and a 12 month high of $9.83.

Insider Buying and Selling at Ardelyx

In related news, CEO Michael Raab sold 41,666 shares of Ardelyx stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $5.31, for a total value of $221,246.46. Following the sale, the chief executive officer now owns 1,129,552 shares of the company’s stock, valued at approximately $5,997,921.12. This trade represents a 3.56 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David M. Mott bought 213,300 shares of the company’s stock in a transaction that occurred on Thursday, December 19th. The stock was purchased at an average cost of $4.67 per share, for a total transaction of $996,111.00. Following the transaction, the director now owns 1,638,765 shares in the company, valued at $7,653,032.55. The trade was a 14.96 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders sold 141,408 shares of company stock worth $761,963. 5.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. GF Fund Management CO. LTD. bought a new position in shares of Ardelyx during the 4th quarter worth approximately $25,000. Newbridge Financial Services Group Inc. bought a new position in shares of Ardelyx during the 4th quarter worth approximately $35,000. SBI Securities Co. Ltd. bought a new position in shares of Ardelyx during the 4th quarter worth approximately $41,000. Quarry LP bought a new position in shares of Ardelyx during the 4th quarter worth approximately $51,000. Finally, Rehmann Capital Advisory Group bought a new position in shares of Ardelyx during the 4th quarter worth approximately $51,000. 58.92% of the stock is currently owned by institutional investors.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.